Literature DB >> 16500685

Acetyl-L-carnitine protects striatal neurons against in vitro ischemia: the role of endogenous acetylcholine.

Barbara Picconi1, Ilaria Barone, Antonio Pisani, Raffaella Nicolai, Paola Benatti, Giorgio Bernardi, Menotti Calvani, Paolo Calabresi.   

Abstract

The neuronal death after ischemia is closely linked to the essential role of mitochondrial metabolism. Inhibition of mitochondrial respiratory chain reduces ATP generation leading to a dysregulation of ion metabolism. Acetyl-L-carnitine (ALC) influences the maintenance of key mitochondrial proteins for maximum energy production and it may play a neuroprotective role in some pathological conditions. In this study we have analyzed ALC-mediated neuroprotection on an in vitro model of brain ischemia. Field potential recordings were obtained from a rat corticostriatal slice preparation. In vitro ischemia (oxygen and glucose deprivation) was delivered by switching to a solution in which glucose was omitted and oxygen was replaced with N2. Ten minutes of in vitro ischemia caused an irreversible loss of the field potential amplitude. Pretreatment with ALC produced a progressive and dose-dependent recovery of the field potential amplitude following in vitro ischemia. The neuroprotective effect of ALC was stereospecific since the pretreatment with two different carnitine-related compounds did not cause neuroprotection. The choline transporter inhibitor hemicholinium-3 blocked the neuroprotective effect of ALC. ALC-mediated neuroprotection was also prevented either by the non-selective muscarinic antagonist scopolamine, or by the putative M2-like receptor antagonist methoctramine. Conversely, the effect of ALC was not altered by the M1-like receptor antagonist pirenzepine. These findings show that ALC exert a neuroprotective action against in vitro ischemia. This neuroprotective effect requires the activity of choline uptake system and the activation of M2 muscarinic receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16500685     DOI: 10.1016/j.neuropharm.2006.01.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

Review 1.  L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.

Authors:  Gustavo C Ferreira; Mary C McKenna
Journal:  Neurochem Res       Date:  2017-05-16       Impact factor: 3.996

2.  Acetyl-L-carnitine and oxaloacetate in post-treatment against LTP impairment in a rat ischemia model. An in vitro electrophysiological study.

Authors:  K Kocsis; L Knapp; J Mészáros; Z Kis; T Farkas; L Vécsei; J Toldi
Journal:  J Neural Transm (Vienna)       Date:  2014-11-29       Impact factor: 3.575

Review 3.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

4.  Correlation between choline signal intensity and acetylcholine level in different brain regions of rat.

Authors:  Xiao-Chuan Wang; Xiao-Xia Du; Qing Tian; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

5.  CSPGs inhibit axon branching by impairing mitochondria-dependent regulation of actin dynamics and axonal translation.

Authors:  Rajiv Sainath; Andrea Ketschek; Leah Grandi; Gianluca Gallo
Journal:  Dev Neurobiol       Date:  2016-08-02       Impact factor: 3.964

6.  Neuroprotective effects of pre-treatment with l-carnitine and acetyl-L-carnitine on ischemic injury in vivo and in vitro.

Authors:  Rui Zhang; Hong Zhang; Zhongxia Zhang; Tao Wang; Jingya Niu; Dongsheng Cui; Shunjiang Xu
Journal:  Int J Mol Sci       Date:  2012-02-15       Impact factor: 6.208

7.  Undifferentiated and differentiated PC12 cells protected by huprines against injury induced by hydrogen peroxide.

Authors:  Marta Pera; Pelayo Camps; Diego Muñoz-Torrero; Belen Perez; Albert Badia; M Victoria Clos Guillen
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.